Human RCTPubMed ID: 29351994·2018
SUSTAIN-7: Semaglutide versus Dulaglutide in Type 2 Diabetes
Wysham C, Bhargava A, Cheng X, et al.
Diabetes Care, 2018 · n = 1623
Key finding
Semaglutide 1.0mg showed greater HbA1c reduction than dulaglutide 1.5mg (1.5% vs 1.2%, p<0.001) with superior weight loss (2.9kg vs 1.8kg).
Summary
Phase 3b trial showing semaglutide superior efficacy compared to dulaglutide GLP-1 receptor agonist.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on Semaglutide
Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)
New England Journal of Medicine · 2023 · Human RCT
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)
New England Journal of Medicine · 2023 · Human RCT
Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)
Nature Medicine · 2022 · Human RCT
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)
JAMA · 2022 · Human RCT
STEP 3: Semaglutide for Weight Management in Severe Obesity
New England Journal of Medicine · 2022 · Human RCT